NPS-1034

Research use only, not for human use.

NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.

NPS-1034 is a novel MET inhibitor, which inhibits the activated MET receptor and its constitutively active mutants. NPS-1034, inhibits various constitutively active mutant forms of MET as well as HGF-activated wild-type MET. NPS-1034 inhibited the proliferation of cells expressing activated MET and promoted the regression of tumors formed from such cells in a mouse xenograft model through anti-angiogenic and pro-apoptotic actions. NPS-1034 also inhibited HGF-stimulated activation of MET signaling in the presence or absence of serum. Notably, NPS-1034 inhibited three MET variants that are resistant to the MET inhibitors SU11274, NVP-BVU972, and PHA665752.

NPS1034; NPS-1034; NPS 1034

Endocrinology/Hormones

AChR

Met; AXL

Others-Field

——

1221713-92-3

551.54

C31H23F2N5O3

98%

DMSO : 34 mg/mL. 61.65 mM;

CN1N(C(=O)C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(=CN4)C3=CC=CC=C3)C(F)=C2)=C1C)C1=CC=C(F)C=C1

N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.

(-20℃)

With Ice Pack

≥ 2 years